Herpes zoster
Therapeutic area
Dermatology
Rare disease
No
- Definition
- A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Herpes zoster
- Therapeutic area
- Dermatology
- herpes zoster
- Zoster
- herpes Zoster
- shingles
- Disease mechanisms
- Acquired
- Severity
- Severe
- Dermatology
- Infectious Disease
- MONDO ID
- MONDO:0005609
- Parent condition
- MONDO:0005608
Related records
Broader conditions (17)
- Disease
- Disease arising from reactivation of latent virus
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Herpesviridae infectious disease
- Human disease
- Infectious disease
- Integumentary system disorder
- Post-infectious disorder
- Post-viral disorder
- Primary viral infectious disease
- Skin disorder
- Skin disorder caused by infection
- Varicella zoster infection
- Vesiculobullous skin disease
- Viral infectious disease
Narrower conditions (3)
- Geniculate herpes zoster
- Ophthalmic herpes zoster
- Zoster sine herpete
Trials (277)
- 3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)
- A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
- A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years
- A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults
- A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
- A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
- A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
- A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older
- A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
- A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
- A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
- A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
- A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster
- A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
- A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)
- A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
- A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster
- A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
Approved drugs (5)
- Acyclovir
- Famciclovir
- Valacyclovir
- Valacyclovir hydrochloride
- Varicella zoster virus envelope glycoprotein E
Drugs in development (13)
- (north)-methanocarbathymidine Phase 1
- Amenamevir Phase 3
- Capsaicin Phase 3
- Crisugabalin Phase 2
- Elasomeran Phase 3
- Gabapentin Phase 3
- Influenza virus vaccine Phase 3
- Pregabalin Phase 3
- Sodium chloride Phase 1
- Sorivudine Phase 2
- Valnivudine hydrochloride Phase 2
- Valomaciclovir stearate Phase 2
- Varicella zoster virus, live attenuated Phase 3